Caregivers' and Physicians' Treatment Preference in Parkinson Patients Treated With Neupro® Requiring Caregiver Support (CARE-ACT)

• Mean score of the caregivers' rating of Neupro® compared to oral anti-Parkinson medication [ Time Frame: After at least one month of treatment with Rotigotine in combination with an oral IPD treatment, measurement (documentation) at a single time point ] [ Designated as safety issue: No ]
  The mean score is calculated from the scores for the single responses which are rated from 'great disadvantages' to 'great advantages' and scored on a 5-point scale from -2 to 2.
• Mean score of the physicians' rating of Neupro® compared to oral anti-Parkinson medication [ Time Frame: Single measurement after at least one month of treatment with Rotigotine in combination with an oral IPD treatment preceding onset of study ] [ Designated as safety issue: No ]
  The mean score is calculated from the scores for the single responses which are rated from 'great disadvantages' to 'great advantages' and scored on a 5-point scale from -2 to 2.

• Assessment of the physicians' rationale for the choice of Neupro® due to substance in idiopathic Parkinsons Disease patients requiring caregiver support [ Time Frame: Single measurement after at least one month of treatment with Rotigotine in combination with an oral IPD treatment preceding onset of study ] [ Designated as safety issue: No ]
• Assessment of the physicians' rationale for the choice of Neupro® due to application form in idiopathic Parkinsons Disease patients requiring caregiver support [ Time Frame: Single measurement after at least one month of treatment with Rotigotine in combination with an oral IPD treatment preceding onset of study ] [ Designated as safety issue: No ]
• Score for the physicians' rating of Neupro® compared to oral anti-Parkinson medication in relation to nausea and/or vomiting in patients with nausea and/or vomiting. [ Time Frame: Single measurement after at least one month of treatment with Rotigotine in combination with an oral IPD treatment preceding onset of study ] [ Designated as safety issue: No ]
  The response is rated on a 5-point scale from -2 to 2.
• Score for the physicians' rating of Neupro® compared to oral anti-Parkinson medication in relation to control of compliance [ Time Frame: Single measurement after at least one month of treatment with Rotigotine in combination with an oral IPD treatment preceding onset of study ] [ Designated as safety issue: No ]
  The response is rated on a 5-point scale from -2 to 2.
• Score for the physicians' rating of Neupro® compared to oral anti-Parkinson medication in relation to multiple medication in patients with multiple medication. [ Time Frame: Single measurement after at least one month of treatment with Rotigotine in combination with an oral IPD treatment preceding onset of study ] [ Designated as safety issue: No ]
  The response is rated on a 5-point scale from -2 to 2.
• Score for the physicians' rating of Neupro® compared to oral anti-Parkinson medication in relation to surgery requiring general anaesthesia. [ Time Frame: Single measurement after at least one month of treatment with Rotigotine in combination with an oral IPD treatment preceding onset of study ] [ Designated as safety issue: No ]
  The response is rated on a 5-point scale from -2 to 2.
• Score for the physicians' rating of Neupro® compared to oral anti-Parkinson medication in relation to dose adaption. [ Time Frame: Single measurement after at least one month of treatment with Rotigotine in combination with an oral IPD treatment preceding onset of study ] [ Designated as safety issue: No ]
  The response is rated on a 5-point scale from -2 to 2.
• Score for the physicians' rating of Neupro® compared to oral anti-Parkinson medication with regard to independency of food administration. [ Time Frame: Single measurement after at least one month of treatment with Rotigotine in combination with an oral IPD treatment preceding onset of study ] [ Designated as safety issue: No ]
  The response is rated on a 5-point scale from -2 to 2.
• Score for the physicians' rating of Neupro® compared to oral anti-Parkinson medication with regard to sleeping patients. [ Time Frame: Single measurement after at least one month of treatment with Rotigotine in combination with an oral IPD treatment preceding onset of study ] [ Designated as safety issue: No ]
  The response is rated on a 5-point scale from -2 to 2.
• Score for the physicians' rating of Neupro® compared to oral anti-Parkinson medication in relation to risk of interaction with other treatments. [ Time Frame: Single measurement after at least one month of treatment with Rotigotine in combination with an oral IPD treatment preceding onset of study ] [ Designated as safety issue: No ]
  The response is rated on a 5-point scale from -2 to 2.
• Score for the physicians' rating of Neupro® compared to oral anti-Parkinson medication in relation to resorption. [ Time Frame: Single measurement after at least one month of treatment with Rotigotine in combination with an oral IPD treatment preceding onset of study ] [ Designated as safety issue: No ]
  The response is rated on a 5-point scale from -2 to 2.
• Score for the caregivers' rating of Neupro® compared to oral anti-Parkinson medication in relation to dysphagia in patients with dysphagia. [ Time Frame: Single measurement after at least one month of treatment with Rotigotine in combination with an oral IPD treatment preceding onset of study ] [ Designated as safety issue: No ]
  The response is rated on a 5-point scale from -2 to 2.
• Score for the caregivers' rating of Neupro® compared to oral anti-Parkinson medication in relation to nausea and/or vomiting in patients with nausea and/or vomiting. [ Time Frame: Single measurement after at least one month of treatment with Rotigotine in combination with an oral IPD treatment preceding onset of study ] [ Designated as safety issue: No ]
  The response is rated on a 5-point scale from -2 to 2.
• Score for the caregivers' rating of Neupro® compared to oral anti-Parkinson medication in relation to control of compliance [ Time Frame: Single measurement after at least one month of treatment with Rotigotine in combination with an oral IPD treatment preceding onset of study ] [ Designated as safety issue: No ]
  The response is rated on a 5-point scale from -2 to 2.
• Score for the caregivers' rating of Neupro® compared to oral anti-Parkinson medication in relation to multiple medication in patients with multiple medication. [ Time Frame: Single measurement after at least one month of treatment with Rotigotine in combination with an oral IPD treatment preceding onset of study ] [ Designated as safety issue: No ]
  The response is rated on a 5-point scale from -2 to 2.
• Score for the caregivers' rating of Neupro® compared to oral anti-Parkinson medication with regard to independency of food administration. [ Time Frame: Single measurement after at least one month of treatment with Rotigotine in combination with an oral IPD treatment preceding onset of study ] [ Designated as safety issue: No ]
  The response is rated on a 5-point scale from -2 to 2.
• Score for the caregivers' rating of Neupro® compared to oral anti-Parkinson medication with regard to sleeping patients. [ Time Frame: Single measurement after at least one month of treatment with Rotigotine in combination with an oral IPD treatment preceding onset of study ] [ Designated as safety issue: No ]
  The response is rated on a 5-point scale from -2 to 2.
• Score for the caregivers' rating of Neupro® compared to oral anti-Parkinson medication in relation to care-giving efforts [ Time Frame: Single measurement after at least one month of treatment with Rotigotine in combination with an oral IPD treatment preceding onset of study ] [ Designated as safety issue: No ]
  The response is rated on a 5-point scale from -2 to 2.

The study objective is to evaluate advantages and disadvantages of Neupro® versus oral anti-Parkinson medication by caregivers and physicians in idiopathic Parkinson's Disease patients requiring caregiver support in nursing home or outpatient care settings.

Idiopathic Parkinson's Disease (iPD) patients treated with a combination of L-dopa or other oral iPD drug and Neupro® for at least one month and requiring caregiver support documented as per medical records

Every consecutive, eligible patient to be treated with Neupro® as per physician's decision

Inclusion Criteria:

• Only patients having signed the consent form regarding study information, data transfer and data use
• The patients suffer from iPD treated with a combination of l-dopa or another oral iPD drug and Neupro® for at least one month
• The patients require caregiver support documented as per medical records (e.g. based on German level of care intensity 1 or greater)
• The decision to prescribe Neupro® must have been made by the physician independent of his/her decision to include the patient in the study.

Exclusion Criteria:

• Patients not fulfilling the inclusion criteria
• And according to SmPC: Hypersensitivity to the active substance or to any of the excipients, magnetic resonance tomography (MRT) or cardioversion